奖赏相关腹侧纹状体活动与舍曲林及安慰剂差异应答
该研究基于EMBARC试验中222例未用药重性抑郁障碍成人,随机接受舍曲林(n=110)或安慰剂(n=112),在治疗前完成奖赏任务功能磁共振成像。结果显示,腹侧纹状体奖赏反应的时间动态索引显著调节第8周抑郁水平(Fs≥9.67,ps≤0.002),且偏离强化学习理论预测的腹侧纹状体反应模式与舍曲林较安慰剂更低第8周抑郁症状相关。
要点
- 腹侧纹状体奖赏反应动态索引显著调节舍曲林与安慰剂在第8周抑郁水平的差异应答。
- 偏离强化学习预测的腹侧纹状体反应模式与舍曲林较安慰剂更好的第8周应答相关。
- 治疗前奖赏相关腹侧纹状体活动可能作为客观神经标记指导个体化抗抑郁药选择。
核心结论
- 治疗前腹侧纹状体对奖赏预期和预测误差的动态反应模式可调节舍曲林与安慰剂的差异应答,偏离强化学习预测越明显者舍曲林较安慰剂第8周抑郁症状更低。
研究设计与样本
- 基于EMBARC研究,222例未用药重性抑郁障碍成人随机接受舍曲林(n=110)或安慰剂(n=112),治疗前完成奖赏任务功能磁共振成像,并以汉密尔顿抑郁评定量表评估8周。
主要发现
- 腹侧纹状体奖赏反应时间动态索引对第8周抑郁水平存在显著调节效应(Fs≥9.67,ps≤0.002)。
- 相对于强化学习理论预测异常越明显的腹侧纹状体反应,与舍曲林组较安慰剂组第8周抑郁症状更低相关。
关键数值与推荐
- 调节效应显著:Fs≥9.67,ps≤0.002;样本为舍曲林n=110、安慰剂n=112,评估工具为HSRD,观察至第8周。
临床怎么用
- 治疗前奖赏相关腹侧纹状体活动可能作为客观神经标记,辅助个体化选择舍曲林等抗抑郁药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.
引用
- Greenberg T, Fournier JC, Stiffler R, et al. Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. Mol Psychiatry. 2019. PMID: 31462766. doi:10.1038/s41380-019-0490-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。